The Brain-Computer Interface Market Is Exploding: Here Are the Numbers That Prove It
- Neuroba
- 1 hour ago
- 15 min read
Brain-computer interface market size figures vary across research firms, but every credible forecast tells the same story: this market is in an early-stage exponential growth curve, fueled by clinical breakthroughs, record-breaking venture capital, and a neurological disease burden that will only intensify as populations age.
This article breaks down the numbers that matter: market size, segment data, funding rounds, regulatory milestones, regional breakdown, competitive positioning, and growth drivers, and explains what they mean for investors, researchers, and technology builders entering the BCI sector in 2026.
What Is the BCI Market and What Does It Include?
The brain-computer interface market encompasses all commercial and research-stage products that create a direct communication pathway between the brain and an external device. This spans three broad product categories:
Invasive BCIs require surgical implantation of electrodes into or onto brain tissue. This category includes fully intracortical systems (Neuralink's N1), endovascular systems (Synchron's Stentrode), and cortical surface arrays (Precision Neuroscience's Layer 7).
Partially invasive or minimally invasive BCIs involve electrode placement within the skull but outside brain tissue, including electrocorticography (ECoG) grids placed on the cortical surface.
Non-invasive BCIs capture neural signals through intact scalp using EEG, fNIRS, MEG, or other modalities without any surgical procedure.
The market also encompasses hardware components (electrodes, amplifiers, processors), software and algorithms (neural decoders, AI systems, firmware), and services (clinical trials, surgical support, data analysis). Different market reports include or exclude different layers of this stack, which explains the wide variance in published market size figures.
For a technical explanation of how these device categories work at the engineering level, see The Core Technologies Powering Today's Brain-Computer Interfaces.
Brain-Computer Interface Market Size: What the Data Actually Shows
The most frequently cited question about the BCI market is also the one with the most divergent answers. Published estimates for the global BCI market in 2025 to 2026 range from approximately $1.3 billion to $4.0 billion, a spread that reflects different scope definitions rather than genuine disagreement about market trajectory.
The following table consolidates the major published estimates with their scope and methodology notes:
Research Firm | 2025/2026 Estimate | 2031-2035 Projection and CAGR |
Precedence Research | $2.94B (2025) | $13.86B by 2035 at 16.77% |
Toward Healthcare | $3.21B (2025) | $15.04B by 2035 at 16.7% |
Grand View Research | Invasive TAM $168B | Multiple segments, varies |
Verified Market Research | $4.02B (2024) | $10.86B by 2032 at 14.61% |
Coherent Market Insights | $3.75B (2026) | $15.04B by 2035 at 16.7% |
Mordor Intelligence | $1.27B (2025) | $2.26B by 2031 at 10.1% |
Global Growth Insights | $1.96B (2025) | $5.20B by 2035 at 10.29% |
The wide spread across firms reflects real methodological differences. Firms that include cochlear implants and deep brain stimulation in their BCI market definition produce higher totals. Firms that restrict scope to BCI-specific neural decoding devices produce lower totals. The growth trajectory is consistent across all: 10% to 17% CAGR, depending on scope.
The most useful working figure for strategic planning: the global BCI market as narrowly defined (excluding cochlear implants and DBS) sits at approximately $3.3 to $3.8 billion in 2026 and is on track for $13 to $15 billion by 2035 at a 16 to 17% CAGR. That figure doubles roughly every 4.5 years.
For context on what a market at this stage looks like in clinical terms, see Brain Computer Interfaces in 2026: The Year Everything Changed.
BCI Market Growth Drivers: Why the Numbers Will Hold
Market forecasts are only as credible as the underlying drivers. For BCI, the growth thesis rests on five structural forces, each of which is independently verifiable and compounding.
Driver 1: Neurological disease burden. The increasing prevalence of neurological disorders, affecting over 15% of the global population, is the primary demand driver for therapeutic BCIs. 11.77 million people globally had Parkinson's disease in 2021. ALS affects approximately 30,000 Americans at any given time, with 5,000 new diagnoses annually. Spinal cord injuries number approximately 17,000 per year in the United States alone. As populations age globally, these figures rise. BCIs are among the few technologies capable of restoring communication and motor function in patients for whom no pharmacological solution exists.
Driver 2: AI-powered decoding performance. A UCLA neuroscience study published in November 2025 demonstrated that integrating an AI copilot into BCI systems significantly enhances performance by filtering neural noise, predicting user intent, and improving control precision. The findings confirmed that AI reduces training time, enhances real-world usability, and accelerates the transition of BCIs from research settings to clinical deployment. The integration of AI is doing to neural decoding what it did to genomic analysis in the early 2010s: transforming an analytical bottleneck into a competitive advantage.
Driver 3: Clinical trial momentum. The number of active BCI clinical trials globally has grown from fewer than 10 per year in the early 2000s to over 150 by 2025. Each completed trial generates safety and efficacy data that de-risks subsequent regulatory applications, compressing the time from laboratory demonstration to clinical standard-of-care.
Driver 4: Expanding application scope. BCI began as a motor restoration technology. It is expanding into speech restoration, memory augmentation, psychiatric treatment, sensory prosthetics, and cognitive enhancement. Each new application opens a distinct clinical market with its own regulatory pathway and reimbursement structure.
Driver 5: Consumer and defense demand. Gaming and entertainment BCI adoption has grown 25% annually in recent years. The defense sector accounts for approximately 15% of current BCI R&D projects globally. DARPA has awarded funds to multiple organizations for its Next-Generation Nonsurgical Neurotechnology (N3) program, with $9.8 million to Rice University researchers alone for non-invasive military neural interface development.
BCI Market Segmentation: Where Revenue Is Concentrated
By Product Type
Non-invasive BCIs currently dominate market revenue by unit volume, accounting for approximately 61.7% of the market in 2026. This dominance reflects the much larger installed base of EEG-based consumer and research devices compared to the small but rapidly growing number of implanted clinical BCIs.
The invasive segment, while a small fraction of current volume, is growing at the fastest rate and carries the highest per-unit revenue. A single implanted BCI system represents a significantly higher value transaction than a consumer EEG headset, and each regulatory approval of an invasive device adds a commercially deployable product to a previously empty clinical market.
Product Segment | 2026 Market Share | Key Players and Growth Rate |
Non-invasive (EEG-based) | 61.7% | Emotiv, OpenBCI, Kernel moderate growth |
Invasive intracortical | Small but fastest growing | Neuralink, Blackrock Neurotech high growth |
Endovascular | Emerging | Synchron very high growth |
Cortical surface (ECoG) | Research-stage | Precision Neuroscience high growth |
Partially invasive | Niche | Various academic programs moderate |
By Application
Application | 2026 Share and CAGR | Clinical Status |
Healthcare and neurorehabilitation | 57%, high CAGR | Active clinical trials |
Communication and control | Fastest growing at 12.78% CAGR | FDA trial stage |
Entertainment and gaming | 12-15%, 25% annual growth | Commercial |
Smart home control | Emerging | Early commercial |
Defense and military | 8-10%, very high CAGR | DARPA-funded R&D |
Education and research | Fastest institutional growth | Active investment |
Within healthcare, neuro-prosthetics and motor restoration captured 49.1% of application revenue in 2025. Communication and control applications are growing at a 12.78% CAGR, reflecting the clinical momentum behind speech BCIs for ALS and locked-in syndrome patients. For a detailed breakdown of where these applications are producing real clinical outcomes, see 15 Real-World Applications of Brain-Computer Interfaces Changing Lives Today.
By Component
Component | 2025 Share | Trend |
Hardware (electrodes, amplifiers, processors) | Largest segment | Steady growth |
Software and algorithms | Fastest growing | AI-driven acceleration |
Services (clinical, surgical, data) | Expanding | Growth with trial volume |
The software and algorithms segment is growing fastest because AI-based neural decoding is where competitive differentiation is accumulating. A BCI system's electrode hardware sets the ceiling on signal quality; the software determines how much of that signal ceiling is actually utilized in clinical performance.
By Interface Type
Motor and output BCIs led with 50.3% revenue share in 2025. Hybrid BCI systems that combine multiple signal types are advancing at a 13.34% CAGR. Communication BCIs (speech and text output) are the fastest-growing interface category.
By End User
End User | 2025 Share | Growth Driver |
Hospitals and clinics | 45.1% | Clinical trial activity and early approvals |
Research and academic institutes | 12.29% CAGR (fastest) | Institutional investment expansion |
Defense and military | Significant and growing | DARPA programs, NATO interest |
Consumer | Large by volume | EEG headset market |
Manufacturing | Emerging | Industrial BCI applications |
Regional Breakdown: Where the BCI Market Is Winning and Where It Is Accelerating
Region | 2025-2026 Share and Growth | Key Driver |
North America | 40.8% to 48.1%, dominant through 2030 | R&D investment, FDA infrastructure, startup ecosystem |
Europe | Part of 68% combined N.Am + Europe | NHS investment, EU AI Act regulatory framework |
Asia-Pacific | Fastest growing at 12.38% CAGR | China's first invasive BCI trial (June 2025), aging demographics |
Middle East | Emerging, high growth | UAE Neuralink PRIME trial (May 2026), healthcare investment |
Rest of World | Small, growing | Tele-rehabilitation, remote neuromonitoring |
North America's dominance reflects several structural advantages: the FDA's Breakthrough Device pathway, the density of leading research institutions, and the venture capital ecosystem that has concentrated BCI investment in U.S.-based companies. In May 2026, the UAE launched the first international Neuralink PRIME trial site outside North America in Abu Dhabi, signaling the market's geographic expansion.
China's first clinical trial for an invasive BCI launched in June 2025, using a high-throughput wireless device implanted in a patient with tetraplegia through minimally invasive surgery. China's entry into invasive BCI clinical trials marks a potentially significant shift in the competitive geography of the market over the 2030s.
Venture Capital and Investment: The Funding Surge
The BCI sector attracted $2.3 billion in venture capital investment in 2024 alone, a more than three-fold increase from 2022 levels. The 2025 to 2026 funding cycle saw over $1.6 billion in disclosed institutional investment in neurotechnology companies, with average round sizes exceeding $100 million.
The following table documents the major BCI funding rounds from 2024 to 2026:
CompanyCompany | Amount and Date | Lead or Notable Investors |
Neuralink Series E | $650M, April 2026 | Existing investors |
Neuralink Series D | $600M, May 2025 | At $9.6B valuation |
Synchron Series D | $200M, November 2025 | Multiple institutional |
Blackrock Neurotech majority | $200M, April 2024 | Tether |
Science Corporation Series C | $104M, April 2025 | Khosla Ventures |
Precision Neuroscience Series C | $102M, December 2024 | Multiple investors |
Paradromics various | $100M+ total, 2022-2025 | Venture plus $18M DARPA and NIH |
Neuralink's total primary funding reached approximately $1.85 billion by mid-2026. The investor roster across the sector includes ARK Invest, Founders Fund, Sequoia Capital, Bezos Expeditions, and Khosla Ventures, institutional names that do not typically move into a sector speculatively.
For a strategic analysis of which companies are attracting this capital and what differentiates them, see The 20 Most Important Brain-Computer Interface Companies Right Now.
Regulatory Milestones: The De-Risking Events That Move Markets
Regulatory approvals and designations are the clearest signal that a medical technology's commercial trajectory is becoming concrete. The BCI sector has accumulated a series of significant regulatory milestones that materially reduce investment risk.
Date | Milestone | Significance for Market |
1984 | FDA approves multi-channel cochlear implant | First commercial neural interface; reimbursement precedent |
1997 | FDA approves DBS for essential tremor | Neural stimulation therapy regulatory pathway created |
2002 | FDA approves DBS for Parkinson's disease | Mass market neural interface enters standard of care |
2013 | FDA approves NeuroPace RNS for epilepsy | First closed-loop neural device approval |
2024 | FDA expands Breakthrough Device pathways for BCIs | Priority review for ALS, SCI, stroke communication devices |
May 2025 | Neuralink receives third FDA Breakthrough Device designation | Multi-indication portfolio de-risked across neurological conditions |
September 2024 | Synchron COMMAND trial reports 12-month positive outcomes | Endovascular BCI safety confirmed at clinically meaningful timeframe |
2025 to 2026 | EU AI Act enters enforcement covering AI-enabled BCIs | Regulatory compliance framework clarified for European market |
The May 2025 Breakthrough Device designation for Neuralink's speech restoration system is particularly significant. It covers individuals with ALS, stroke, spinal cord injury, cerebral palsy, multiple sclerosis, and other neurological conditions, combining multiple patient populations under a single regulatory track. This is Neuralink's third such designation, confirming the FDA's recognition of BCIs as a priority clinical technology category rather than an edge case.
For a detailed breakdown of how BCIs are currently used in medical settings and what the approval trajectory means clinically, see How Brain-Computer Interfaces Are Revolutionizing Modern Medicine.
Competitive Landscape: Where the Market Value Is Being Built
The BCI market's competitive structure has consolidated around a small number of heavily funded, clinically active companies, with a longer tail of academic programs and earlier-stage startups. Understanding the differentiation between the leading companies is essential for understanding where market value will accumulate.
Company | Device and Approach | Human Trial Status and Funding |
Neuralink | N1 (Telepathy) intracortical, 1,024 electrodes, robotic implant | 21 participants across 4 countries; ~$1.85B raised |
Synchron | Stentrode endovascular, no open surgery | COMMAND trial, 6+ U.S. patients; $200M+ Series D |
Precision Neuroscience | Layer 7 cortical surface, slit incision | 50+ intraoperative human recordings; ~$155M total |
Blackrock Neurotech | Utah Array intracortical research standard | 30+ implanted patients, 15-year data; $200M Tether |
Paradromics | High-density cortical ECoG | First human recording June 2025; $100M+ |
Science Corporation | Orion cortical visual prosthetic | Clinical trials ongoing; ~$250-290M |
BrainGate Consortium | Utah Array academic research standard | Largest published human BCI dataset; NIH funded |
The most commercially significant recent development is Synchron's platform integrations. In August 2025, Synchron became the first BCI company to link its device to an Apple iPad, allowing a patient with ALS to navigate apps and compose text through thought alone. The same patient subsequently controlled an Apple Vision Pro headset and used Amazon Alexa to manage smart home functions without hands, voice, or eyes. These are not engineering demonstrations. They are distribution partnerships connecting BCI capability to ecosystems used by hundreds of millions of people globally.
In January 2025, Synchron announced a collaboration with NVIDIA's Holoscan platform to advance real-time neural interaction and edge AI processing for next-generation implantable BCIs. The Synchron-NVIDIA partnership is among the clearest signals that BCI has entered the AI infrastructure investment conversation rather than remaining exclusively within medtech.
For a full ranked and reviewed breakdown of BCI devices in 2026, see Best Brain-Computer Interfaces in 2026: Ranked and Reviewed. For a focused comparison of invasive versus non-invasive approaches, see Invasive Brain-Computer Interfaces: The Science Behind Brain Implants and Non-Invasive Brain-Computer Interfaces: How They Work Without Surgery.
The AI Premium: Why the Decoding Layer Is the High-Value Asset
Standard BCI market analyses consistently underweight one structural factor: the AI layer above the hardware is where the highest-margin, most scalable, and most defensible revenue will accumulate over the next decade.
Neural decoding algorithms, foundation models trained on neural data, and AI-powered signal processing pipelines are the primary competitive differentiator between BCI systems with comparable hardware specifications. This distinction has major implications for market structure and valuation:
Hardware commoditizes. Electrode materials, amplifier circuits, and wireless transmission protocols are subject to manufacturing cost curves, open-source research dissemination, and component supplier competition. The performance ceiling of a hardware generation eventually gets reached and surpassed.
AI compounds. Neural decoding models trained on longitudinal patient data improve with more data, generalize across patients through transfer learning, and create proprietary datasets that competitors cannot replicate without clinical access. The first company to train a foundation model on thousands of patients' intracortical data will have a structural advantage that hardware improvements alone cannot overcome.
Synchron's Chiral cognitive foundation model, announced in March 2025, is the first explicit acknowledgment from a major BCI company that the AI layer is a primary product, not just a component. Neuralink's proprietary decoding stack, which achieved 8.0 bits per second cursor control with Noland Arbaugh despite losing 85% of its electrode threads to retraction, demonstrated that algorithmic compensation can partially offset hardware failure.
Nearly 52% of new BCI market growth is being driven by AI-based systems and wearable technology, reflecting the field-wide recognition that intelligence, not instrumentation, is the growth engine.
For Neuroba's analysis of this convergence, see The Future of Brain-Computer Interfaces: AI and Quantum Tech Leading the Way.
Market Challenges: What Could Slow the Growth Curve
No investment thesis is complete without an honest account of the headwinds. The BCI market faces four structural challenges that could compress the growth curve below current projections.
Cost and accessibility. Advanced BCI systems, particularly invasive implants, remain expensive to manufacture, implant, and maintain. Invasive BCI systems represent approximately 30% of total market expenditures, and the high cost of development, regulatory compliance, and specialized surgical procedures creates a significant barrier to broad adoption. Nearly 40% of the global population faces affordability constraints that would limit access to high-end BCI systems even after regulatory approval.
Long-term signal stability. The primary technical challenge for implanted BCIs remains maintaining signal quality over years. Electrode encapsulation by glial scar tissue degrades recording quality over months to years for most current electrode materials. Flexible polymer threads reduce but do not eliminate this problem. Without reliable long-term signal stability, chronic implanted BCIs cannot achieve the 10-plus year useful life that clinical economics require.
Regulatory timelines. High-risk medical devices face extensive regulatory pathways. Even with Breakthrough Device designation, the path from first-in-human trial to commercial approval typically spans five to ten years. Regulatory compliance adds approximately 20% to product development timelines. International regulatory fragmentation means that a U.S. approval does not automatically open European or Asian markets.
Data privacy and neural rights. Evolving regulations around neural data ownership and cybersecurity vulnerabilities represent a policy risk that could add compliance costs and slow commercial deployment. Chile enacted the world's first constitutional neurorights amendment in 2021. Spain, Colombia, and several other jurisdictions have advanced neurorights legislation in 2025 to 2026. The EU AI Act classifies AI-enabled BCI systems as high-risk devices requiring transparency, explainability, and human oversight requirements. These frameworks are emerging faster than industry compliance standards.
The Five-Year Investment Thesis: 2026 to 2031
The BCI market in 2031 will look categorically different from the market in 2026. Based on current clinical trajectories, regulatory timelines, and competitive dynamics, the following developments are high-probability within the five-year window:
First, at least one invasive BCI will achieve FDA premarket approval (PMA) for a therapeutic indication, likely ALS or high cervical spinal cord injury communication restoration. This will be the triggering event for third-party payer reimbursement negotiations and health technology assessment processes that determine whether BCIs enter standard clinical practice.
Second, the invasive BCI segment will grow from a research and expanded-access market to a commercial market. The current patient population receiving invasive BCIs in clinical trials will expand to thousands as approved devices enter clinical deployment. Per-device revenue, currently embedded in trial costs, will shift to commercial pricing structures.
Third, the AI decoding layer will emerge as a distinct commercial product category, with software subscription and platform revenue supplementing hardware revenue. Companies with proprietary neural datasets will command valuation premiums that reflect the data moat, not just the device installed base.
Fourth, non-invasive BCIs will close the performance gap with invasive systems in specific application domains, particularly workplace cognitive monitoring, mental health diagnostics, and gaming. The $2.1 billion non-invasive wearable neurotechnology market will expand as consumer BCI devices achieve performance thresholds that make them meaningfully useful rather than novelty products.
Fifth, the geographic distribution of the BCI market will shift. China's clinical entry in 2025 and the UAE's Neuralink trial site in 2026 are early signals of a market that will become genuinely global in the 2030s.
For Neuroba's ten specific predictions for where BCI technology goes from here, see The Future of BCI Technology: 10 Predictions for the Next Decade.
Frequently Asked Questions: BCI Market
What is the current size of the BCI market?
The global BCI market is estimated between $2.94 billion and $4.02 billion in 2025 to 2026, depending on scope definition. Figures that include cochlear implants and DBS produce higher totals. The market excluding established neuromodulation devices sits at approximately $3.3 to $3.8 billion in 2026.
What is the projected BCI market size by 2035?
The most frequently cited projections place the global BCI market between $10.86 billion (Verified Market Research, 2032 endpoint) and $15.04 billion (Toward Healthcare and Coherent Market Insights, 2035 endpoint) at a CAGR of 14.6% to 16.77%.
Which segment of the BCI market is growing fastest?
The invasive BCI segment is growing at the fastest rate by product type. The communication and control application segment is growing at the fastest rate by application. The research and academic end-user segment is growing at the fastest institutional rate (12.29% CAGR). By region, Asia-Pacific is growing fastest.
Which region dominates the BCI market?
North America dominates, accounting for 40.8% to 48.1% of global BCI market revenue in 2025 to 2026. The United States specifically accounts for the majority of North American revenue, driven by DARPA investment, FDA infrastructure, and the concentration of leading BCI companies including Neuralink, Synchron, Precision Neuroscience, and Blackrock Neurotech.
How much venture capital has gone into BCI companies?
The BCI sector attracted $2.3 billion in venture capital in 2024 alone. The 2025 to 2026 cycle has seen over $1.6 billion in disclosed institutional investment. Neuralink alone has raised approximately $1.85 billion in total primary funding through April 2026.
What are the biggest risks to BCI market growth?
The primary risks are: high development and manufacturing costs limiting affordability, long-term electrode signal stability issues in implanted devices, lengthy regulatory approval timelines, international regulatory fragmentation, and emerging neurorights legislation that could add compliance requirements. Infrastructure costs and lack of trained neurosurgeons in lower-income markets also constrain global adoption.
Who are the leading companies in the BCI market?
As of 2026, the leading invasive BCI companies are Neuralink, Synchron, Precision Neuroscience, and Blackrock Neurotech. In non-invasive BCIs, Emotiv, OpenBCI, Kernel, and NeuroSky lead by market presence. Academic consortia including BrainGate (Brown University and Stanford) maintain the largest published human BCI research dataset.
Key Takeaways
The global BCI market is valued at $2.94 billion to $4.02 billion in 2025 to 2026 and is projected to reach $10.86 to $15.04 billion by 2031 to 2035 at a 14.6% to 16.77% CAGR.
Non-invasive BCIs hold 61.7% of the market by product share; invasive BCIs are growing at the fastest rate.
Healthcare accounts for 57% of BCI market revenue; communication and control is the fastest-growing application.
North America holds 40.8% to 48.1% of global revenue; Asia-Pacific is the fastest-growing region.
The BCI sector attracted $2.3 billion in venture capital in 2024 alone; the 2025 to 2026 cycle has seen $1.6 billion in additional institutional investment.
Neuralink raised $650M in April 2026, reaching approximately $1.85 billion in total funding at a $9.6 billion valuation.
Neuralink received its third FDA Breakthrough Device designation, for speech restoration, in May 2025.
Synchron integrated its BCI with Apple iPad, Apple Vision Pro, and Amazon Alexa in 2025, establishing platform-level distribution.
Nearly 52% of new BCI market growth is driven by AI-based systems and wearable technology.
The AI neural decoding layer is increasingly the primary competitive and valuation differentiator between BCI companies.
Market headwinds include high development costs, electrode signal stability challenges, regulatory timelines, and emerging neurorights compliance requirements.
First FDA premarket approval for a therapeutic invasive BCI is the pivotal event that will trigger commercial market formation, widely expected within the 2026 to 2031 window.
References
Precedence Research. Brain Computer Interface Market Size to Hit USD 13.86 Billion by 2035. January 2026. https://www.precedenceresearch.com/brain-computer-interface-market
Toward Healthcare. Brain Computer Interface Market to Grow at 16.7% CAGR till 2035. May 2026. https://www.towardshealthcare.com/insights/brain-computer-interface-market
Coherent Market Insights. Brain Computer Interface Market Size and Forecast 2026 to 2034. https://www.coherentmarketinsights.com/market-insight/brain-computer-interface-market-4467
Verified Market Research. Brain Computer Interface Market USD 10.86 Billion by 2032. January 2026. https://finance.yahoo.com/news/brain-computer-interface-bci-market-150300408.html
Grand View Research. Brain Computer Interface Market Size. December 2025. https://www.grandviewresearch.com/industry-analysis/brain-computer-interfaces-market
Mordor Intelligence. Brain Computer Interface Market Size and Forecast 2026 to 2031. January 2026. https://www.mordorintelligence.com/industry-reports/brain-computer-interface-market
Global Growth Insights. Brain Computer Interface Market Size Share 2035. April 2026. https://www.globalgrowthinsights.com/market-reports/brain-computer-interface-market-105929
SNS Insider. Brain Computer Interface Market Size Share and Industry Growth. https://www.snsinsider.com/reports/brain-computer-interface-market-4473
Verified Market Reports. Global Brain Computer Interface BCI Market Size Industry Share Trends and Forecast 2026 to 2034. May 2026. https://www.verifiedmarketreports.com/product/brain-computer-interface-bci-market/
Sacra. Neuralink valuation, funding and news. April 2026. https://sacra.com/c/neuralink/
Medical Device Network. Neuralink wins FDA breakthrough tag for speech restoration. May 2025. https://www.medicaldevice-network.com/news/neuralink-wins-fda-breakthrough-tag-for-speech-restoration/
MedTech Dive. Synchron raises $200M to prepare for brain computer interface launch. November 2025. https://www.medtechdive.com/news/synchron-funding-bci-200m/804977/
Neuro Founders. The Big 6 of BCI: Where Neurotech Funding Is Flowing. November 2025. https://www.neurofounders.co/post/the-big-6-of-bci-where-neurotech-funding-is-flowing
Quick Market Pitch. Which VCs are funding BCI technology? July 2025. https://quickmarketpitch.com/blogs/news/brain-computer-interfaces-investors
Ellty. Brain-Computer Interface Investors. December 2025. https://www.ellty.com/blog/brain-computer-interface-investors
DARPA N3 Program. Next-Generation Nonsurgical Neurotechnology. https://www.darpa.mil/program/next-generation-nonsurgical-neurotechnology
Nature. High-performance neuroprosthesis for speech decoding and avatar control. 2023. https://www.nature.com
NIH BRAIN Initiative. https://www.nih.gov